MBX Biosciences, Inc. Common Stock (MBX) - Total Assets
Based on the latest financial reports, MBX Biosciences, Inc. Common Stock (MBX) holds total assets worth $452.70 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of MBX Biosciences, Inc. Common Stock to assess how comfortably operating cash covers total debt obligations.
MBX Biosciences, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how MBX Biosciences, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See MBX net assets for net asset value and shareholders' equity analysis.
MBX Biosciences, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
MBX Biosciences, Inc. Common Stock's total assets of $452.70 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.6% |
| Accounts Receivable | $2.12 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how MBX Biosciences, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MBX Biosciences, Inc. Common Stock (MBX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MBX Biosciences, Inc. Common Stock's current assets represent 99.1% of total assets in 2025, an increase from 98.0% in 2022.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2025, down from 53.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
MBX Biosciences, Inc. Common Stock Competitors by Total Assets
Key competitors of MBX Biosciences, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
MBX Biosciences, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 30.79 | 23.31 | 21.26 |
| Quick Ratio | 30.79 | 23.31 | 21.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $433.97 Million | $233.79 Million | $79.54 Million |
MBX Biosciences, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between MBX Biosciences, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.44 |
| Latest Market Cap to Assets Ratio | 4.57 |
| Asset Growth Rate (YoY) | 43.4% |
| Total Assets | $385.14 Million |
| Market Capitalization | $1.76 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values MBX Biosciences, Inc. Common Stock's assets at a significant premium (4.57x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: MBX Biosciences, Inc. Common Stock's assets grew by 43.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of MBX Biosciences, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $385.14 Million | +43.42% |
| 2024-12-31 | $268.54 Million | +219.00% |
| 2023-12-31 | $84.18 Million | +86.67% |
| 2022-12-31 | $45.09 Million | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more